Previous 10 | Next 10 |
home / stock / bayzf / bayzf news
Bayer's defensive business mix, along with prodding for change from an activist investor, seemed to catalyze the stock's outperformance during Q1 2022. Mittleman Investement Management (MIM) hasn't owned a large cap pharmaceutical company since a very successful foray into Pfizer just...
Mittleman Investment Management, LLC (“MIM”) is an SEC-registered investment adviser that provides discretionary portfolio management to institutional investors and high-net-worth individuals. The Mittleman Global Value Equity Fund (MGVEF) declined 13.1% in Q1 2022. ...
Bayer Aktiengesellschaft (BAYZF) Q1 2022 Results Conference Call May 10, 2022 08:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, the Crop Science Division Stefan Oelrich - Head, the Pharmaceuticals Division Conference...
The war in Ukraine continues to dominate market movements. I have started exiting one of my apartment REITs and predominantly focus on adding dividend income via select purchases. The combination of soaring inflation and geopolitical uncertainty has rattled markets and following t...
We allocated 3% of the portfolio to Siemens Energy AG. SMEGF has the opportunity to leverage several significant trends over the coming years. We hope to build to a 6% position in due time but think that the market may give us an opportunity to buy cheaper. For further detai...
German conglomerate Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) announced on Tuesday that the U.S. Food and Drug Administration (FDA) granted the priority review and accepted its supplemental New Drug Application ((sNDA)) for prostate cancer therapy Nubeqa. With the sNDA, Bayer (OTCPK:BAYRY) has reques...
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...
The Food and Drug Administration (FDA) granted priority review to AstraZeneca's (NASDAQ:AZN) application for a single priming dose of tremelimumab added to Imfinzi (durvalumab) to treat patients with unresectable hepatocellular carcinoma, a type of liver cancer. The British drugmaker's had su...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The war in Ukraine has catalyzed greater alignment among ...
Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) submitted an application to China's National Medical Products Administration (NMPA) seeking expanded use of Nubeqa (darolutamide) in combination with chemotherapy docetaxel to treat adult patients with metastatic hormone sensitive prostate...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG Registered Shares Company Name:
BAYZF Stock Symbol:
OTCMKTS Market:
NORTHAMPTON, MA / ACCESSWIRE / August 29, 2023 / Bayer - As climate change quickens, societal expectations increase and the threat of resistance grows, new crop protection solutions are imperative. Advances in the life sciences and data-driven technologies hold the key to expanding our pipeline ...
Monsanto Must Face Georgia State Jurors in Lawsuit Over Cancer-Causing Roundup Herbicide PR Newswire 11th Circuit opinion finds chemical giant subject to state's warning label laws Nachawati Law Group trial lawyers gearing up for next Roundup cancer trial in Au...
Bayer Runs Out of Appeals at US Supreme Court as Thousands of Cancer Lawsuits Await over Roundup Herbicide PR Newswire Fears Nachawati trial lawyers gearing up for next Roundup cancer trial in August WASHINGTON , June 22, 2022 /PRNewswire/ -- Baye...